Format

Send to

Choose Destination
MAbs. 2015;7(1):32-41. doi: 10.4161/19420862.2015.989047.

Recombinant renewable polyclonal antibodies.

Author information

1
a New Mexico Consortium ; Los Alamos , NM USA.

Abstract

Only a small fraction of the antibodies in a traditional polyclonal antibody mixture recognize the target of interest, frequently resulting in undesirable polyreactivity. Here, we show that high-quality recombinant polyclonals, in which hundreds of different antibodies are all directed toward a target of interest, can be easily generated in vitro by combining phage and yeast display. We show that, unlike traditional polyclonals, which are limited resources, recombinant polyclonal antibodies can be amplified over one hundred million-fold without losing representation or functionality. Our protocol was tested on 9 different targets to demonstrate how the strategy allows the selective amplification of antibodies directed toward desirable target specific epitopes, such as those found in one protein but not a closely related one, and the elimination of antibodies recognizing common epitopes, without significant loss of diversity. These recombinant renewable polyclonal antibodies are usable in different assays, and can be generated in high throughput. This approach could potentially be used to develop highly specific recombinant renewable antibodies against all human gene products.

KEYWORDS:

CTBP, C-terminal binding protein; ELISA, enzyme linked immunosorbant assay; HCDR3, Heavy chain complementarity determining region 3; HPA, Human Protein Atlas; scFv, single chain Fv; PrESTs, Protein epitope signature tag; rrpAbs, recombinant renewable poly; antibody validation; phage display; polyclonal recombinant antibodies; yeast display

PMID:
25530082
PMCID:
PMC4622072
DOI:
10.4161/19420862.2015.989047
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center